NEW YORK (GenomeWeb News) – Life Technologies today said that it has signed an agreement to supply Novartis with its Dynabeads for use in immunotherapeutics being developed by the drug firm for cancer.

The agreement includes a license to Life Tech's intellectual property to perform the resulting therapy and it is exclusive for use in the field of chimeric antigen receptors for the treatment of cancer. Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.